FDA commish cheers on biosimilars as Amgen, Allergan score OK for knockoff of Roche's Avastin
Roche now has another big biosimilar rival to contend with.
The FDA has OK’d Mvasi, a knockoff of a drug that earned $3 billion in the US — $7 billion worldwide — last year as a mainstay in Roche’s drug portfolio. Amgen and Allergan — which wound up with marketing rights after it emerged on top after a series of mergers over the last 5 years — can now start lining up a launch, as the big companies scrap over the patents that expire in 2018 and 2019.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
